Results 11 to 20 of about 15,000 (182)
Journal of Community Hospital Internal Medicine Perspectives, 2021 Background and objectives Anemia is a prevalent complication endured by patients with chronic renal disease. Renal anemia also leads to the development of cardio-vascular complications.
Muhammad Nadeem Ahsan +7 more
doaj +1 more source
Hyporesponsiveness to recombinant human erythropoietin [PDF]
Nephrology Dialysis Transplantation, 2001 The introduction of recombinant human erythropoietin (rh-Epo, epoetin) as a treatment for the anaemia of renal failure has transformed the management of this condition. Nevertheless, a significant number of patients fail to respond. There are many different possible causes of inadequate response to epoetin.
openaire +2 more sources
Allergy, Asthma & Clinical Immunology, 2018 Background Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need for desensitization are rare.
Jaime S. Rosa +3 more
doaj +1 more source
Effect of erythropoietin in treatment of renal anemia in a sample of Iraqi patient [PDF]
Al Ameen Journal of Medical Sciences, 2021 Background: Anemia is a common complication of chronic kidney disease and it is associated with a reduce in the quality of life of patients, it contributes an increase in morbidity and mortality and accelerates the rate of progression of chronic kidney ...
Ali J. Hashim Al Saedi +1 more
doaj
Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells
Revista Brasileira de Hematologia e Hemoterapia, 2016 Background: Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels.
Oscar Andrés Penuela +2 more
doaj +1 more source
Медицинская иммунология, 2020 Our aim was to characterize anti-EPO antibodies in serum samples of the patients treated with erythropoietin. 106 serum samples from the patients treated with erythropoietin (EPO) were collected and assayed.
A. M. Kudryashova +5 more
doaj +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2013 Anemia is a common concomitant disorder in dialysis patients. The responsiveness to recombinant human erythropoietin in hemodialysis (HD) patients with relative hypoparathyroidism [4 ≤ intact parathyroid hormone (iPTH) ≤16.5 pmol/L] remains undetermined.
Khalid Al Saran +2 more
doaj +1 more source
Macrophages as novel target cells for erythropoietin
Haematologica, 2010 Background Our original demonstration of immunomodulatory effects of erythropoietin in multiple myeloma led us to the search for the cells in the immune system that are direct targets for erythropoietin.
Lilach Lifshitz +4 more
doaj +1 more source
Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues. [PDF]
PLoS ONE, 2015 Several clinical trials in oncology have reported increased mortality or disease progression associated with erythropoiesis-stimulating agents. One hypothesis proposes that erythropoiesis-stimulating agents directly stimulate tumor proliferation and/or ...
Scott D Patterson +7 more
doaj +1 more source
Erythropoietin resistance in end-stage renal disease patient with gastric antral vascular ectasia
Brazilian Journal of Nephrology, 2015 We observed a case of recombinant human erythropoietin resistance caused by Gastric Antral Vascular Ectasia in a 40-year-old female with ESRD on hemodialysis.
Desiree Ji Re Lee +6 more
doaj +3 more sources